Lung Cancer Clinical Trials

Showing 1781-1800 of 4,288 trials

An Observational Study to Evaluate Neoadjuvant Nivolumab (OPDIVO®) in Combination With Platinum-Based Chemotherapy in Non-Metastatic Non-Small Cell Lung Cancer Participants in Germany

NCT06169956

The purpose of this observational study is to collect and evaluate real-world data to assess the effectiveness of neoadjuvant nivolumab when given in combination with platinum-based chemotherapy in participants with early-stage, resectable non-small cell lung cancer (NSCLC) in Germany

Resectable Non-small Cell Lung Cancer

Bristol-Myers Squibb400 participantsStarted Nov 2023

Kempten (Allgäu), Bavaria, Germany

RECRUITINGPhase 1

A Randomised Trial of Chemotherapy Plus Surgery for Recurrent Non-Small Cell Lung Cancer

NCT02889666

The purpose of this study is to determine if the commonly administered chemotherapeutic agents including cisplatin, carboplatin, oxaliplatin, docetaxel and gemcitabine for solid tumors in clinical oncology, either a single format or given as combinations followed by surgery are effective in the treatment of relapsed and refractory non-small cell lung cancer patients.

Recurrent Non-small Cell Lung Cancer

Shanghai Jiao Tong University School of Medicine500 participantsStarted Jan 2008

Changchun, Jilin, China • Shanghai, China • Shanghai, China

An Observational Study to Evaluate Neoadjuvant Nivolumab (OPDIVO®) in Combination With Platinum-Based Chemotherapy in Non-Metastatic Non-Small Cell Lung Cancer Participants in Germany

A Randomised Trial of Chemotherapy Plus Surgery for Recurrent Non-Small Cell Lung Cancer

Related Searches

The Efficacy and Safety of PD-1/PD-L1 Inhibitors Combined With Centipeda Minima (CM) in Lung Cancer

Relationship Between Hand Dynamometer Measurements, PFT, and mFI With Postoperative Outcomes

Targeted Natural Killer (NK) Cell Based Adoptive Immunotherapy for the Treatment of Patients With Non-Small Cell Lung Cancer (NSCLC) After Radiochemotherapy (RCT)

To Establish a Molecular Typing System for Early Diagnosis of Lung Cancer

LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II Trial

Clinical Trial of TJ271 Injection Combined With Pembrolizumab in the Treatment of Advanced Solid Tumors

Plasma Metabolic Biomarkers for Multi-Cancer Diagnosis

Study of PF-07263689 in Participants With Selected Advanced Solid Tumors

Real World Study of Lolatinib for Advanced ALK+ NSCLC Patients

Pilot Trial of E Cigarettes in Pts Diagnosed With Cancer of the Head, Neck, and Lung

Integrating Artificial Intelligence Into Lung Cancer Screening.

Dose Tapering and Early Discontinuation to InCreAse cosT-effectIveness Of Immunotherapy for NSCLC

Phase I/IIa Study of H002 in NSCLC With Active EGFR Mutation

A Single-arm Pilot Study of Tislelizumab Combined With Anlotinib in Patients With Advanced NSCLC With Driver-negative After Progression to Immunotherapy

A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF)

Improving Access and Recruitment to Clinical Trials for Lung Cancer Patients

Improving Access to Lung Cancer Clinical Trials